VP4 Stock Overview
Through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.23 |
| 52 Week High | NOK 2.29 |
| 52 Week Low | NOK 1.79 |
| Beta | 0.89 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 14.48% |
| 5 Year Change | n/a |
| Change since IPO | 130.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| VP4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | n/a | -18.4% | 9.1% |
Return vs Industry: Insufficient data to determine how VP4 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VP4 performed against the German Market.
Price Volatility
| VP4 volatility | |
|---|---|
| VP4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VP4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine VP4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 75 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| VP4 fundamental statistics | |
|---|---|
| Market cap | €94.42m |
| Earnings (TTM) | €5.27m |
| Revenue (TTM) | €36.62m |
17.9x
P/E Ratio2.6x
P/S RatioIs VP4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VP4 income statement (TTM) | |
|---|---|
| Revenue | NOK 426.52m |
| Cost of Revenue | NOK 148.95m |
| Gross Profit | NOK 277.57m |
| Other Expenses | NOK 216.20m |
| Earnings | NOK 61.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 65.08% |
| Net Profit Margin | 14.39% |
| Debt/Equity Ratio | 1.8% |
How did VP4 perform over the long term?
See historical performance and comparison